Business Context and Reporting Period
This Form 8-K filing by Benitec Biopharma Inc. (BNTC) reports on events occurring on September 15, 2021. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
- Discretionary Bonus (FY 2021): $225,000 for Dr. Jerel Banks (CEO) and $111,340 for Megan Boston (Executive Director).
- Base Salary Increase (Effective Sept 16, 2021): Dr. Banks to $520,000; Ms. Boston to $317,550.
- Currency Conversion: Ms. Boston's figures were converted from AUD to USD at a rate of 0.73.
Material Changes
There are no material changes to financial performance reported. The material change is the increase in annual base salaries for the CEO and Executive Director, effective September 16, 2021, following the approval of performance-based bonuses for the fiscal year ended June 30, 2021.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, risk factors, or contingencies. Regarding future compensation, the target annual discretionary bonus for the fiscal year ending June 30, 2022, remains unchanged at 50% of base salary for Dr. Banks and 40% for Ms. Boston.
Investor Verification Checklist
- Verify the total cash outflow impact of the approved bonuses and salary increases on the company's liquidity.
- Confirm the exact AUD to USD conversion rate used for Ms. Boston's compensation if reviewing original Australian records.
- Review the company's cash position to ensure these increased fixed costs are sustainable given the company's current funding status.